Repurposing methuosis-inducing anticancer drugs for anthelmintic therapy

PLoS Pathog. 2024 Sep 5;20(9):e1012475. doi: 10.1371/journal.ppat.1012475. eCollection 2024 Sep.

Abstract

Drug-resistant parasitic nematodes pose a grave threat to plants, animals, and humans. An innovative paradigm for treating parasitic nematodes is emphasized in this opinion. This approach relies on repurposing methuosis (a death characterized by accumulation of large vacuoles) inducing anticancer drugs as anthelmintics. We review drugs/chemicals that have shown to kill nematodes or cancerous cells by inducing multiple vacuoles that eventually coalesce and rupture. This perspective additionally offers a succinct summary on Structure-Activity Relationship (SAR) of methuosis-inducing small molecules. This strategy holds promise for the development of broad-spectrum anthelmintics, shedding light on shared molecular mechanisms between cancer and nematodes in response to these inducers, thereby potentially transforming both therapeutic domains.

Publication types

  • Review

MeSH terms

  • Animals
  • Anthelmintics* / pharmacology
  • Antineoplastic Agents* / pharmacology
  • Drug Repositioning*
  • Humans
  • Nematoda / drug effects
  • Neoplasms / drug therapy

Substances

  • Anthelmintics
  • Antineoplastic Agents

Grants and funding

The authors acknowledge the support from the management of SRMIST, Kattankulathur, Tamil Nadu, India. A part of the research was supported by the National Research Foundation of Korea (NRF) funded by the Korean government (MSIT) (2021R1A2C1008368) to JL and by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (RS-2024-00450423) to JL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.